BRCA 2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer

Michael J Pishvaian*, Andrew V Biankin*, Peter Bailey, David K Chang, Daniel Laheru, Christopher L Wolfgang and Jonathan R Brody Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow G31 2ER, UK; Faculty of Medicine, South Western Sydney Clinical School, University of NSW, Liverpool, New South Wales 2170, Australia; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Department of Surgery, Johns Hopkins University, Baltimore, MD, USA and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA